UK-based personalized medicine company DxS expanded the marketing of its TheraScreen K-RAS Mutation test after European regulators narrowed the indication for the metastatic colorectal cancer drug Vectibix to include only patients whose tumor carries the wildtype KRAS gene.

Get the full story with GenomeWeb Premium

Only $95 for the first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.